The Herald Sun's Paul Glider reports that "beer and biotechnology does not sound like a recipe for success but it's a match made in hoppy heaven for the research team at Starpharma".

Go to the article (external link)

The benefits of Starpharma’s DEP™ docetaxel drug which is currently in clinical trials, has been featured nationally on Channel 9 News.

Watch the video (external link)

In this Issue:

› Phase 1 DEP™ docetaxel clinical trial update
› DEP™ docetaxel in the news
› Partner news
› Starpharma targeting key growth areas in Oncology
› Bacterial vaginosis: Prevention of recurrence/Symptomatic relief
› VivaGel® condom
› Corporate news
› Starpharma half yearly financial results

Download: Shareholder Update March 2015 (pdf file, 1MB)

Starpharma today announced that Chief Executive Officer, Dr Jackie Fairley will present at both the leading ROTH Conference in California and the ASX Spotlight conference in New York in the coming week. 

Starpharma is presenting to more than 200 investors at ASX Investor Series event in Sydney.

 The ASX Investor Series is hosted by the ASX in conjunction with Finance News Network (FNN) and is designed to engage the investment community and bring together ASX-listed companies, investors and financial market participants.

Watch Interview Video

Starpharma today released its interim report and financial results for the half-year ended 31 December 2014.

Financial Summary

• Reported loss of $8.5M (Dec 2013: $5.6M)
• Cash position at 31 December 2014 of $39.3M
• R&D tax incentives of $1.6M reported in the half-year (Dec 2013: $2.6M)
• Receipt of $4.2M R&D tax incentive refund
• $20.5M net proceeds from equity placement and share purchase plan

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2014.

Starpharma today announced that CEO Dr Jackie Fairley will present at the 7^th Annual Biotech Showcase^TM conference in San Francisco this week. The Biotech Showcase^TM coincides with the Annual J.P. Morgan Healthcare Conference, which Starpharma is also attending.

Starpharma today announced that the planned launch timing of the VivaGel^® condom in Japan would be delayed following a review of the specific category of medical device classification by the Japanese regulatory authorities.

Starpharma today announced the completion of the regulatory requirements to allow for marketing of the VivaGel^® condom in New Zealand under the brand Lifestyles^® Dual Protect™.